Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

December 31, 2024

Study Completion Date

June 1, 2025

Conditions
PAISNeonatal StrokePerinatal Stroke
Interventions
DRUG

Darbepoetin Alfa

Darbepoetin alfa (Aranesp, Amgen) 2 doses of 10 microgram/kg i.v.

DRUG

Saline

The placebo will consist of saline, containing 9.0 g of salt per liter (0.90%) i.v.

Trial Locations (1)

3584 EA

RECRUITING

Wilhelmina Childrens Hostpital/University Medical Center Utrecht, Utrecht

All Listed Sponsors
collaborator

Alberta Children's Hospital

OTHER

collaborator

The Hospital for Sick Children

OTHER

lead

UMC Utrecht

OTHER